2 terminated, 1 completed, 1 recruiting. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Terminated 2, Completed 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Multiple Sclerosis, Secondary Progressive: new trials by email Literature Review of Multiple Sclerosis, Secondary Progressive trials Research Report on Multiple Sclerosis, Secondary Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). Cladribine Subcutaneous Injection, 0.9% Chloride Injection Sodium - Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis | Phase 2 / Phase 3 | Recruiting | Institute of Psychiatry and Neurology, Warsaw | 188 | 2022-10-03 | 2023-07-28 |
| BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis dimethyl fumarate, Placebo - Multiple Sclerosis, Secondary Progressive | Phase 3 | Terminated | Biogen | 58 | 2015-05-01 | 2017-04-26 |
| Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis Masitinib, Placebo - Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive | Phase 3 | Completed | AB Science | 656 | 2011-08-01 | 2020-04-08 |
| Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis MBP8298 - Multiple Sclerosis, Secondary Progressive | Phase 3 | Terminated | BioMS Technology Corp. | 510 | 2007-06-01 | 2009-08-13 |
Multiple Sclerosis, Chronic Progressive (4) · Multiple Sclerosis (3)
Autoimmune Diseases (4) · Autoimmune Diseases of the Nervous System (4) · Chronic Disease (4) · Demyelinating Autoimmune Diseases, CNS (4) · Demyelinating Diseases (4) · Disease Attributes (4) · Immune System Diseases (4) · Nervous System Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Multiple Sclerosis (1)
Dimethyl Fumarate (1) · MBP-8298 (1) · masitinib (1)
AB Science (1) · BioMS Technology Corp. (1) · Biogen (1) · Institute of Psychiatry and Neurology, Warsaw (1)
Poland (3) · Belgium (1) · Bulgaria (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Netherlands (1) · Romania (1) · Slovakia (1) · Spain (1) · United States (1)
Clyde E Markowitz, MD (1) · Iwona Kurkowska-Jastrzebska, MD, PhD (1) · Patrick Vermersch, MD, PhD (1)
2014 (1)